Merck Millipore Introduces Cellvento™ CHO-100, a Chemically-defined, Non-animal Origin Media for Superior Cell Growth and Productivity

• Designed specifically for long-term growth of CHO-S cells
• Chemically-defined, non-animal origin medium provides improved batch-to-batch consistency
• Yields high cell densities for efficient cell culture and productivity

September 5, 2012, Billerica, MA — Merck Millipore, the Life Science division of Merck, today announced the launch of Cellvento™ CHO-100, a non-animal origin, chemically-defined medium that provides strong cell growth, high productivity and lot-to-lot consistency. The new media formulation was designed for the long-term growth of Chinese Hamster Ovary (CHO) cells to express antibodies or protein products, which will save biopharmaceutical manufacturers time and effort.

“The Cellvento™ CHO-100 cell culture medium is a significant addition to our Pharm Chemical Solutions business,” said Dr. Antoine Heron, Head of Biopharm Materials & Technologies. “It delivers outstanding lot-to-lot consistency in physico-chemical characteristics as well as in growth and production profiles, optimizing the cell culture process and allowing manufacturers to bring protein products to market faster.”

As a non-animal origin, chemically-defined medium, Cellvento™ CHO-100 contains no hydrolysates or components of unknown composition. It was designed to achieve high cell densities in batch mode operation, which is essential to efficient cell culture productivity. Cellvento™ CHO-100 is produced as a powder at the company’s cGMP-compliant facility using high grade raw materials meeting the company’s stringent requirements, leading to reliable product homogeneity that results in effective powder dissolution and uniform component distribution.

For more information please visit: www.merckmillipore.com/cellvento

About Merck Millipore
Merck Millipore is the Life Science division of Merck KGaA of Germany and offers a broad range of innovative, performance products, services and business relationships that enable our customers’ success in research, development and production of biotech and pharmaceutical drug therapies. Through dedicated collaboration on new scientific and engineering insights, and as one of the top three R&D investors in the Life Science Tools industry, Merck Millipore serves as a strategic partner to customers and helps advance the promise of life science.

Headquartered in Billerica, Massachusetts, the division has around 10,000 employees, operations in 67 countries and 2011 revenues of EUR 2.4 billion. Merck Millipore operates as EMD Millipore in the U.S. and Canada.

Note: Merck KGaA or Merck shall mean Merck KGaA, Darmstadt, Germany